January 31, 2017 09:09 AM EST
Pharma

On a deal spree, Take­da grabs Japan­ese cabo rights in $145M pact with Ex­elix­is

Arsalan Arif

Founder

A deal-hun­gry Take­da has stepped up with a $145 mil­lion pact to part­ner with Ex­elix­is on cabozan­ti­nib.

Ex­elix­is $EX­EL grabbed a $50 mil­lion up­front …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

No­vo Nordisk’s Ca­griSe­ma shows 15.7% weight loss in sec­ond piv­otal tri­al

Beam shares promis­ing first clin­i­cal da­ta on gene edit­ing treat­ment for a lung and liv­er dis­ease 

How blue­bird's buy­out of­fer went from $100M up­front to $29M

Sun Phar­ma to ac­quire Check­point Ther­a­peu­tics and its an­ti-PD-L1 an­ti­body

Ex­clu­sive: Dai­ichi Sankyo, John­son & John­son part­ner with RNA de­liv­ery start­up No­sis Bio

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times